Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

85 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Mitogen-activated protein kinase phosphatase-1 in human breast cancer independently predicts prognosis and is repressed by doxorubicin.
Rojo F, González-Navarrete I, Bragado R, Dalmases A, Menéndez S, Cortes-Sempere M, Suárez C, Oliva C, Servitja S, Rodriguez-Fanjul V, Sánchez-Pérez I, Campas C, Corominas JM, Tusquets I, Bellosillo B, Serrano S, Perona R, Rovira A, Albanell J. Rojo F, et al. Among authors: tusquets i. Clin Cancer Res. 2009 May 15;15(10):3530-9. doi: 10.1158/1078-0432.CCR-08-2070. Epub 2009 May 5. Clin Cancer Res. 2009. PMID: 19417026
Deficiency in p53 is required for doxorubicin induced transcriptional activation of NF-кB target genes in human breast cancer.
Dalmases A, González I, Menendez S, Arpí O, Corominas JM, Servitja S, Tusquets I, Chamizo C, Rincón R, Espinosa L, Bigas A, Eroles P, Furriol J, Lluch A, Rovira A, Albanell J, Rojo F. Dalmases A, et al. Among authors: tusquets i. Oncotarget. 2014 Jan 15;5(1):196-210. doi: 10.18632/oncotarget.1556. Oncotarget. 2014. PMID: 24344116 Free PMC article.
Gene expression profiling in true interval breast cancer reveals overactivation of the mTOR signaling pathway.
Rojo F, Domingo L, Sala M, Zazo S, Chamizo C, Menendez S, Arpi O, Corominas JM, Bragado R, Servitja S, Tusquets I, Nonell L, Macià F, Martínez J, Rovira A, Albanell J, Castells X. Rojo F, et al. Among authors: tusquets i. Cancer Epidemiol Biomarkers Prev. 2014 Feb;23(2):288-99. doi: 10.1158/1055-9965.EPI-13-0761. Epub 2013 Dec 17. Cancer Epidemiol Biomarkers Prev. 2014. PMID: 24347552
Defective Cyclin B1 Induction in Trastuzumab-emtansine (T-DM1) Acquired Resistance in HER2-positive Breast Cancer.
Sabbaghi M, Gil-Gómez G, Guardia C, Servitja S, Arpí O, García-Alonso S, Menendez S, Arumi-Uria M, Serrano L, Salido M, Muntasell A, Martínez-García M, Zazo S, Chamizo C, González-Alonso P, Madoz-Gúrpide J, Eroles P, Arribas J, Tusquets I, Lluch A, Pandiella A, Rojo F, Rovira A, Albanell J. Sabbaghi M, et al. Among authors: tusquets i. Clin Cancer Res. 2017 Nov 15;23(22):7006-7019. doi: 10.1158/1078-0432.CCR-17-0696. Epub 2017 Aug 18. Clin Cancer Res. 2017. PMID: 28821558
Are ER+PR+ and ER+PR- breast tumors genetically different? A CGH array study.
Carracedo A, Salido M, Corominas JM, Rojo F, Ferreira BI, Suela J, Tusquets I, Corzo C, Segura M, Espinet B, Cigudosa JC, Arumi M, Albanell J, Serrano S, Solé F. Carracedo A, et al. Among authors: tusquets i. Cancer Genet. 2012 Apr;205(4):138-46. doi: 10.1016/j.cancergen.2012.01.001. Cancer Genet. 2012. PMID: 22559974
Poly (ADP-ribose) polymerase inhibition enhances trastuzumab antitumour activity in HER2 overexpressing breast cancer.
García-Parra J, Dalmases A, Morancho B, Arpí O, Menendez S, Sabbaghi M, Zazo S, Chamizo C, Madoz J, Eroles P, Servitja S, Tusquets I, Yelamos J, Lluch A, Arribas J, Rojo F, Rovira A, Albanell J. García-Parra J, et al. Among authors: tusquets i. Eur J Cancer. 2014 Oct;50(15):2725-34. doi: 10.1016/j.ejca.2014.07.004. Epub 2014 Aug 12. Eur J Cancer. 2014. PMID: 25128455
Non-canonical NF-κB pathway activation predicts outcome in borderline oestrogen receptor positive breast carcinoma.
Rojo F, González-Pérez A, Furriol J, Nicolau MJ, Ferrer J, Burgués O, Sabbaghi M, González-Navarrete I, Cristobal I, Serrano L, Zazo S, Madoz J, Servitja S, Tusquets I, Albanell J, Lluch A, Rovira A, Eroles P. Rojo F, et al. Among authors: tusquets i. Br J Cancer. 2016 Jul 26;115(3):322-31. doi: 10.1038/bjc.2016.204. Epub 2016 Jul 12. Br J Cancer. 2016. PMID: 27404455 Free PMC article.
High Numbers of Circulating CD57+ NK Cells Associate with Resistance to HER2-Specific Therapeutic Antibodies in HER2+ Primary Breast Cancer.
Muntasell A, Servitja S, Cabo M, Bermejo B, Pérez-Buira S, Rojo F, Costa-García M, Arpí O, Moraru M, Serrano L, Tusquets I, Martínez MT, Heredia G, Vera A, Martínez-García M, Soria L, Comerma L, Santana-Hernández S, Eroles P, Rovira A, Vilches C, Lluch A, Albanell J, López-Botet M. Muntasell A, et al. Among authors: tusquets i. Cancer Immunol Res. 2019 Aug;7(8):1280-1292. doi: 10.1158/2326-6066.CIR-18-0896. Epub 2019 Jun 12. Cancer Immunol Res. 2019. PMID: 31189644
Polysomy of chromosome 17 in breast cancer tumors showing an overexpression of ERBB2: a study of 175 cases using fluorescence in situ hybridization and immunohistochemistry.
Salido M, Tusquets I, Corominas JM, Suarez M, Espinet B, Corzo C, Bellet M, Fabregat X, Serrano S, Solé F. Salido M, et al. Among authors: tusquets i. Breast Cancer Res. 2005;7(2):R267-73. doi: 10.1186/bcr996. Epub 2005 Jan 26. Breast Cancer Res. 2005. PMID: 15743507 Free PMC article.
85 results